ANTecedent Annular Reduction to Facilitate TransCatheter TrICuspid Valve Replacement (ANTARCTIC) Authors: Ahmad Jabri, Luai Madanat, Richard Bloomingdale, Adam Foglesong, Amr Abbas, Brian Renard, Douglas Horstmanshof, Ivan D. Hanson Published: 2026 ABSTRACT BackgroundTranscatheter tricuspid valve implantation may not be possible when annular size is very large.Case SummaryWe present an 85-year-old man who developed NYHA functional class III symptoms and recurrent heart failure hospitalizations due to severe tricuspid regurgitation and right ventricular dysfunction. Marked annular enlargement precluded primary transcatheter tricuspid valve replacement. Transcatheter edge-to-edge repair with a PASCAL device achieved partial tricuspid regurgitation reduction and annular remodeling. Follow-up imaging demonstrated reduced annular dimensions, enabling successful staged transcatheter tricuspid valve replacement with a 56-mm EVOQUE valve.DiscussionSevere tricuspid regurgitation with right ventricular dysfunction and extreme annular enlargement is difficult to treat with existing transcatheter therapies.Take-Home MessagesStaged transcatheter edge-to-edge repair–facilitated transcatheter tricuspid valve replacement approach is feasible. An 85-year-old man with heart failure with preserved ejection fraction, stage 3 chronic kidney disease, and persistent atrial fibrillation presented with NYHA functional class III symptoms and recurrent heart failure hospitalizations. Transesophageal echocardiography demonstrated torrential tricuspid regurgitation (TR) with severe right ventricular (RV) dilation and dysfunction (Video 1). Right heart catheterization revealed a mean pulmonary artery pressure of 30 mm Hg, right atrial pressure of 17 mm Hg, pulmonary capillary wedge pressure of 15 mm Hg, and pulmonary vascular resistance of 2 Wood units. Cardiac computed tomography angiography showed a markedly enlarged RV and a diastolic tricuspid annular perimeter of 175 mm, with restricted systolic leaflet closure and a large central coaptation defect (Figure 1). Given prohibitive surgical risk and annular dimensions unsuitable for transcatheter tricuspid valve replacement (TTVR) with EVOQUE, the multidisciplinary heart team elected to proceed with transcatheter edge-to-edge repair.Figure 1Baseline Assessment and Staged TEER-Facilitated Transcatheter Tricuspid Valve Replacement Procedural Imaging(A and B) TEE demonstrating severe TR with RV dysfunction. (C) Computed tomography angiography demonstrating tricuspid annular enlargement pre-TEER. (D and E) TEE demonstrating residual severe TR. (F) Computed tomography angiography demonstrating improvement in tricuspid annular size post-TEER. (G and H) Manipulation and positioning of the EVOQUE delivery system. (I and J) Angiography post successful EVOQUE valve implantation. (K and L) TEE post transcatheter tricuspid valve deployment demonstrating optimal anchoring and no paravalvular leak. ICE = intracardiac echocardiography; RV = right ventricle; TEE = transesophageal echocardiography; TEER = transcatheter edge-to-edge repair; TR = tricuspid regurgitation; TV = tricuspid valve. Baseline Assessment and Staged TEER-Facilitated Transcatheter Tricuspid Valve Replacement Procedural Imaging (A and B) TEE demonstrating severe TR with RV dysfunction. (C) Computed tomography angiography demonstrating tricuspid annular enlargement pre-TEER. (D and E) TEE demonstrating residual severe TR. (F) Computed tomography angiography demonstrating improvement in tricuspid annular size post-TEER. (G and H) Manipulation and positioning of the EVOQUE delivery system. (I and J) Angiography post successful EVOQUE valve implantation. (K and L) TEE post transcatheter tricuspid valve deployment demonstrating optimal anchoring and no paravalvular leak. ICE = intracardiac echocardiography; RV = right ventricle; TEE = transesophageal echocardiography; TEER = transcatheter edge-to-edge repair; TR = tricuspid regurgitation; TV = tricuspid valve. A PASCAL device was successfully implanted at the most prominent TR jet in the antero-septal commissure, with partial reduction in TR. Additional attempts with an ACE device at the P2–S and P1–S positions resulted in unstable implant position and unsatisfactory reduction in TR. Given improvement in TR severity from torrential to severe, the procedure was concluded, with plans to reassess candidacy for TTVR following annular remodeling. Repeat computed tomography angiography demonstrated reduction in tricuspid annular dimensions, with a diastolic perimeter of 166 mm, and confirmed stable positioning of the PASCAL device across the anterior and septal leaflets (Figure 1). Subsequently, TTVR was performed via right and left femoral venous access using a 7-F sheath, exchanged for a steerable Agilis Nxt sheath (Abbott) for RV navigation. A curved Safari wire (Boston Scientific) was positioned at the RV apex, and the EVOQUE delivery system (Edwards Lifesciences) was advanced into the RV. Under transesophageal echocardiographic guidance, a 56-mm EVOQUE valve was deployed using stepwise unsheathing, achieving optimal anchoring and full expansion without paravalvular leak (Figure 1). The PASCAL implant rested between EVOQUE anchors and remained stable throughout EVOQUE implantation. The patient was discharged after 3 days and remains clinically stable on follow-up. This case highlights the feasibility of staged transcatheter edge-to-edge repair–facilitated TTVR as a minimally invasive treatment strategy for complex TR in patients with challenging annular anatomy. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.